FDA approval based on Phase 3 data demonstrating statistically significant improvements in progression‑free survival and overall survival versus standard of…
Read More
SHELTON, Conn., March 6, 2026 /PRNewswire/ — Intensity Therapeutics, Inc. (“Intensity” or “the Company”) (Nasdaq: INTS), a late-stage clinical biotechnology…
Read More
A national distribution network with robust reach enables broad access to QIVIGY across specialty pharmacies, infusion centers, hospitals, and other…
Read More
SHANGHAI, March 6, 2026 /PRNewswire/ — CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on developing innovative CAR…
Read More